References and Notes
<A NAME="RD27006ST-1A">1a</A>
Patel M.
McHugh RJ.
Cordova BC.
Klabe RM.
Erickson-Viitanen S.
Trainor GL.
Ko SS.
Bioorg. Med. Chem. Lett.
1999,
9:
3221
<A NAME="RD27006ST-1B">1b</A>
El-Shafei HA.
Badr-Eldin SM.
Egypt. J. Microbiol.
1994,
27:
353
<A NAME="RD27006ST-1C">1c</A>
Sugimoto H,
Yonaga M,
Karibe N,
Limura Y,
Nagato S,
Sasaki A,
Yamanishi Y,
Ogura H,
Kosasa T,
Uchikoshi K, and
Yamatsu K. inventors; Eur. Patent Appl. Ep 468 187.
; Chem. Abstr. 1992,
116, 235643
<A NAME="RD27006ST-1D">1d</A>
Waxman L.
Darke PL.
Antiviral Chem. Chemother.
2000,
11:
1
<A NAME="RD27006ST-1E">1e</A>
Girgis AS.
Pharmazie
2000,
466
<A NAME="RD27006ST-2">2</A>
Latif N.
Mishriky N.
Assad FM.
Aust. J. Chem.
1982,
35:
1037
<A NAME="RD27006ST-3">3</A>
Wang Y.
Li X.
Ding K.
Tetrahedron: Asymmetry
2002,
13:
1291
<A NAME="RD27006ST-4">4</A>
Ikeda K.
Morimoto T.
Sekia M.
Chem. Pharm. Bull.
1980,
1178
<A NAME="RD27006ST-5">5</A>
Szatmari I.
Hetenyi A.
Lazar L.
Fulop F.
J. Heterocyclic Chem.
2004,
41:
367
<A NAME="RD27006ST-6">6</A>
Cimarelli C.
Palmieri G.
Volpini E.
Can. J. Chem.
2004,
82:
1314
<A NAME="RD27006ST-7A">7a</A>
Betti M.
Gazz. Chim. Ital.
1900,
30II:
310
<A NAME="RD27006ST-7B">7b</A>
Betti M.
Org. Synth., Coll. Vol. I
1941,
381
<A NAME="RD27006ST-8A">8a</A>
Domling A.
Ugi I.
Angew. Chem. Int. Ed.
2000,
39:
3168
<A NAME="RD27006ST-8B">8b</A>
Ugi I.
Domling A.
Endeavour
1994,
18:
115
<A NAME="RD27006ST-8C">8c</A>
Heck S.
Domling A.
Synlett
2000,
424
<A NAME="RD27006ST-9A">9a</A>
Shaabani A.
Bazgir A.
Tetrahedron Lett.
2004,
45:
2575
<A NAME="RD27006ST-9B">9b</A>
Shaabani A.
Dabiri M.
Bazgir A.
Dyes Pigm.
2006,
71:
68
<A NAME="RD27006ST-9C">9c</A>
Bazgir A.
J. Chem. Res., Synop.
2006,
1
<A NAME="RD27006ST-9D">9d</A>
Shaabani A.
Bazgir A.
Teimouri F.
Tetrahedron Lett.
2003,
44:
857
<A NAME="RD27006ST-10A">10a</A>
Shaabani A.
Bazgir A.
Mol. Div.
2004,
8:
141
<A NAME="RD27006ST-10B">10b</A>
Shaabani A.
Teimouri MB.
Bazgir A.
Bijanzadeh HR.
Mol. Div.
2003,
6:
199
<A NAME="RD27006ST-10C">10c</A>
Mohammad Pour-Amini M.
Shaabani A.
Bazgir A.
Catal. Commun.
2006,
7:
843
<A NAME="RD27006ST-11">11</A>
Typical procedure for the preparation of 1,2-dihydro-1-phenylnaphtho[1,2-
e
][1,3]oxazine-3-one (4a) under thermal solvent-free conditions: A mixture of β-naphthol (1 mmol), benzaldehyde (1 mmol), urea (1.5 mmol) and PTSA
(0.3 mmol) was finely mixed together. The reaction mixture was placed in a screw-capped
vial and heated at 160 °C for 1.5 h. After cooling, the reaction mixture was washed
with H2O and then recrystallized from EtOAc-hexane (1:3) to afford the pure product 4a as a white powder (58%).
<A NAME="RD27006ST-12">12</A>
Typical procedure under microwave-assisted conditions: A mixture of β-naphthol (1 mmol), benzaldehyde (1 mmol) and urea (1.5 mmol) were
finely mixed together. The reaction mixture was placed in a screw-capped vial and
irradiated for 6 min with a power of 900 W. After cooling, the reaction mixture was
washed with H2O and then recrystallized from EtOAc-hexane (1:3) to afford the pure product 4a (81%); mp 218-220 °C; IR (KBr): 3295, 1730, 1517 cm-1; 1H NMR (300 MHz, DMSO-d
6): δ = 6.19 (d, J = 2.1 Hz, 1 H, CH), 7.24-8.00 (m, 11 H, Ar-H), 8.87 (br s, 1 H, NH); 13C NMR (75 MHz, DMSO-d
6): δ = 54.20, 114.50, 117.32, 123.57, 125.54, 127.42, 127.81, 128.47, 129.08, 129.32,
129.41, 130.68, 130.86, 143.34, 147.85, 149.77; MS (ESI): m/z (%) = 275 (7) [M+], 231 (100), 202 (35), 51 (24).
<A NAME="RD27006ST-13A">13a</A>
Kappe CO.
J. Org. Chem.
1997,
62:
7201
<A NAME="RD27006ST-13B">13b</A>
Huang S.
Pan Y.
Zhu Y.
Wu A.
Org. Lett.
2005,
7:
3797
<A NAME="RD27006ST-13C">13c</A>
Cristau P.
Vors J.
Zhu JP.
Tetrahedron Lett.
2003,
44:
5575
<A NAME="RD27006ST-13D">13d</A>
Dondoni A.
Massi A.
Minghini E.
Bertolasi V.
Tetrahedron
2004,
60:
2311
<A NAME="RD27006ST-14">14</A>
Selected characterization data:
1,2-Dihydro-1-(4-methylphenyl)naphtho[1,2-
e
][1,3]oxazine-3-one (4b): mp 166-16 °C; IR (KBr): 3230, 3139, 1717 cm-1; 1H NMR (300 MHz, DMSO-d
6): δ = 2.21 (s, 3 H, CH3), 6.13 (d, J = 2.4 Hz, 1 H, CH), 7.10-7.99 (m, 10 H, Ar-H), 8.81 (s, 1 H, NH); 13C NMR (75 MHz, DMSO-d
6): δ = 21.06, 53.98, 114.61, 117.29, 123.56, 125.49, 127.32, 127.76, 129.05, 129.33,
129.89, 130.59, 130.85, 137.78, 140.43, 147.80, 149.81; MS (ESI): m/z (%) = 290 (10) [M+ + H], 231 (100), 202 (20).
1,2-Dihydro-1-(4-chlorophenyl)naphtho[1,2-
e
][1,3]oxazine-3-one (4f): mp 208-210 °C; IR (KBr): 3224, 3146, 1734 cm-1; 1H NMR (300 MHz, DMSO-d
6): δ = 6.24 (s, 1 H, CH), 7.31-8.01 (m, 10 H, Ar-H), 8.91 (s, 1 H, NH); 13C NMR (75 MHz, DMSO-d
6): δ = 53.42, 114.02, 117.34, 123.50, 125.62, 127.91, 128.06, 129.13, 129.23, 129.37,
129.42, 130.87, 133.06, 142.22, 147.90, 149.61; MS (ESI): m/z (%) = 309 (5) [M+], 265 (60), 231 (100), 202 (27), 115 (15).
1-{[2-Hydroxynaphthalen-1-yl](phenyl) methyl} urea (intermediate 5): mp 190-192 °C; IR (KBr): 3463, 3406, 3347, 3219, 1664 cm-1; 1H NMR (300 MHz, CD3SOCD3): δ = 5.82 (s, 2 H, NH2, exchanges with D2O), 6.91-7.81 (m, 13 H), 9.94 (br s, 1 H, OH); 13C NMR (75 MHz, CD3SOCD3): δ = 48.56, 119.05, 120.58, 122.72, 123.27, 126.22, 126.81, 128.26, 128.69, 129.0,
129.33, 132.71, 144.77, 153.51, 159.01; MS (ESI): m/z (%): 275 (5) [M+ - NH3], 231 (100), 202 (15), 144 (100).